NCT01350258 2025-05-31
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
Phase 1/2 Terminated
Clinical Trials
13 trialsNCT00566098 2023-05-26
Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00469209 2020-09-24
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00985907 2020-06-17
DMV
University of California, San Francisco
Phase 1/2 Terminated
NCT00477750 2019-10-11
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT01875237 2019-07-16
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01079936 2016-06-06
Lenalidomide and High-Dose Melphalan
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00406978 2016-05-10
MPTD
University of Turin, Italy
Phase 1/2 Completed
NCT01279694 2016-04-13
CARMYSAP
Nantes University Hospital
Phase 1/2 Completed
NCT00602706 2011-05-16
Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
Mayo Clinic
Phase 1/2 Completed
NCT00004158 2010-09-21
Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00248430 2010-09-21
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00045136 2009-04-03
Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Completed